Epidemiological, clinical, and histological characteristics of NLPHL and cHL
| . | NLPHL . | cHL . |
|---|---|---|
| Incidence | 0.1-0.2/100 000/y | 2-4/100 000/y |
| Male/female ratio | 3:1 | 1.3:1 |
| Median age, y | 37 | 33 |
| Stage at diagnosis | ||
| Early, % | 63 | 22 |
| Intermediate, % | 16 | 39 |
| Advanced, % | 21 | 39 |
| Risk factors | ||
| Elevated ESR, % | 4 | 45 |
| ≥3 lymph node areas involved, % | 28 | 55 |
| Extranodal disease, % | 6 | 14 |
| Large mediastinal mass, % | 31 | 55 |
| Histological marker | ||
| CD20 | + | ± |
| CD30 | − | + |
| CD45 | + | − |
| CD15 | − | + |
| CD79a | + | ± |
| . | NLPHL . | cHL . |
|---|---|---|
| Incidence | 0.1-0.2/100 000/y | 2-4/100 000/y |
| Male/female ratio | 3:1 | 1.3:1 |
| Median age, y | 37 | 33 |
| Stage at diagnosis | ||
| Early, % | 63 | 22 |
| Intermediate, % | 16 | 39 |
| Advanced, % | 21 | 39 |
| Risk factors | ||
| Elevated ESR, % | 4 | 45 |
| ≥3 lymph node areas involved, % | 28 | 55 |
| Extranodal disease, % | 6 | 14 |
| Large mediastinal mass, % | 31 | 55 |
| Histological marker | ||
| CD20 | + | ± |
| CD30 | − | + |
| CD45 | + | − |
| CD15 | − | + |
| CD79a | + | ± |
Adapted from Nogová et al28 with permission. cHL, classical Hodgkin lymphoma; ESR, erythrocyte sedimentation rate; NLPHL, nodular lymphocyte-predominant Hodgkin lymphoma.